#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Bone disorders , especially osteoporosis , are becoming increasingly prevalent as the aging population grows , and bone fractures also occur frequently .
2-1	16-20	Bone	person|abstract[3]	new|new[3]	appos|coref	2-4[4_3]|5-1
2-2	21-30	disorders	abstract[3]	new[3]	_	_
2-3	31-32	,	_	_	_	_
2-4	33-43	especially	abstract[4]	giv[4]	coref	10-20[67_4]
2-5	44-56	osteoporosis	abstract[4]	giv[4]	_	_
2-6	57-58	,	_	_	_	_
2-7	59-62	are	_	_	_	_
2-8	63-71	becoming	_	_	_	_
2-9	72-84	increasingly	_	_	_	_
2-10	85-94	prevalent	_	_	_	_
2-11	95-97	as	_	_	_	_
2-12	98-101	the	person[5]	new[5]	_	_
2-13	102-107	aging	person[5]	new[5]	_	_
2-14	108-118	population	person[5]	new[5]	_	_
2-15	119-124	grows	_	_	_	_
2-16	125-126	,	_	_	_	_
2-17	127-130	and	_	_	_	_
2-18	131-135	bone	object|event[7]	new|new[7]	coref|coref	4-4|13-32[83_7]
2-19	136-145	fractures	event[7]	new[7]	_	_
2-20	146-150	also	_	_	_	_
2-21	151-156	occur	_	_	_	_
2-22	157-167	frequently	_	_	_	_
2-23	168-169	.	_	_	_	_

#Text=Osteoporosis contributes significantly to global healthcare costs , and the treatment of osteoporosis remains a great challenge .
3-1	170-182	Osteoporosis	abstract	new	coref	3-13
3-2	183-194	contributes	_	_	_	_
3-3	195-208	significantly	_	_	_	_
3-4	209-211	to	_	_	_	_
3-5	212-218	global	abstract[10]	new[10]	_	_
3-6	219-229	healthcare	organization|abstract[10]	new|new[10]	_	_
3-7	230-235	costs	abstract[10]	new[10]	_	_
3-8	236-237	,	_	_	_	_
3-9	238-241	and	_	_	_	_
3-10	242-245	the	event[11]	new[11]	_	_
3-11	246-255	treatment	event[11]	new[11]	_	_
3-12	256-258	of	event[11]	new[11]	_	_
3-13	259-271	osteoporosis	event[11]|abstract	new[11]|giv	coref	4-17
3-14	272-279	remains	_	_	_	_
3-15	280-281	a	abstract[13]	new[13]	_	_
3-16	282-287	great	abstract[13]	new[13]	_	_
3-17	288-297	challenge	abstract[13]	new[13]	_	_
3-18	298-299	.	_	_	_	_

#Text=Thus , new bone anabolic drugs need to be developed for the prevention and treatment of osteoporosis .
4-1	300-304	Thus	_	_	_	_
4-2	305-306	,	_	_	_	_
4-3	307-310	new	substance[15]	new[15]	_	_
4-4	311-315	bone	object|substance[15]	giv|new[15]	coref	5-22
4-5	316-324	anabolic	substance[15]	new[15]	_	_
4-6	325-330	drugs	substance[15]	new[15]	_	_
4-7	331-335	need	_	_	_	_
4-8	336-338	to	_	_	_	_
4-9	339-341	be	_	_	_	_
4-10	342-351	developed	_	_	_	_
4-11	352-355	for	_	_	_	_
4-12	356-359	the	abstract[16]	new[16]	_	_
4-13	360-370	prevention	abstract[16]	new[16]	_	_
4-14	371-374	and	_	_	_	_
4-15	375-384	treatment	event[17]	new[17]	_	_
4-16	385-387	of	event[17]	new[17]	_	_
4-17	388-400	osteoporosis	event[17]|abstract	new[17]|giv	coref	10-20
4-18	401-402	.	_	_	_	_

#Text=Bone morphogenetic protein 2 ( BMP2 ) is one of the most important growth factors that induce osteoblast differentiation and stimulate bone or cartilage formation .
5-1	403-407	Bone	person|substance[20]	giv|new[20]	_	_
5-2	408-421	morphogenetic	substance[20]	new[20]	_	_
5-3	422-429	protein	substance[20]	new[20]	_	_
5-4	430-431	2	substance[20]	new[20]	_	_
5-5	432-433	(	_	_	_	_
5-6	434-438	BMP2	abstract	new	coref	6-1
5-7	439-440	)	_	_	_	_
5-8	441-443	is	_	_	_	_
5-9	444-447	one	abstract[22]	new[22]	_	_
5-10	448-450	of	abstract[22]	new[22]	_	_
5-11	451-454	the	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-12	455-459	most	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-13	460-469	important	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-14	470-476	growth	abstract[22]|abstract|abstract[24]	new[22]|new|new[24]	_	_
5-15	477-484	factors	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-16	485-489	that	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-17	490-496	induce	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-18	497-507	osteoblast	abstract[22]|abstract[24]|event|event[26]	new[22]|new[24]|new|new[26]	coref|coref	9-12|9-11[53_26]
5-19	508-523	differentiation	abstract[22]|abstract[24]|event[26]	new[22]|new[24]|new[26]	_	_
5-20	524-527	and	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-21	528-537	stimulate	abstract[22]|abstract[24]	new[22]|new[24]	_	_
5-22	538-542	bone	abstract[22]|abstract[24]|object|event[29]	new[22]|new[24]|giv|new[29]	coref|coref	6-11|6-11[33_29]
5-23	543-545	or	abstract[22]|abstract[24]|event[29]	new[22]|new[24]|new[29]	_	_
5-24	546-555	cartilage	abstract[22]|abstract[24]|place|event[29]	new[22]|new[24]|new|new[29]	_	_
5-25	556-565	formation	abstract[22]|abstract[24]|event[29]	new[22]|new[24]|new[29]	_	_
5-26	566-567	.	_	_	_	_

#Text=BMP2 has been widely used in the clinic to promote bone formation .
6-1	568-572	BMP2	abstract	giv	coref	7-7
6-2	573-576	has	_	_	_	_
6-3	577-581	been	_	_	_	_
6-4	582-588	widely	_	_	_	_
6-5	589-593	used	_	_	_	_
6-6	594-596	in	_	_	_	_
6-7	597-600	the	place[31]	new[31]	_	_
6-8	601-607	clinic	place[31]	new[31]	_	_
6-9	608-610	to	_	_	_	_
6-10	611-618	promote	_	_	_	_
6-11	619-623	bone	object|event[33]	giv|giv[33]	coref|coref	9-26|19-27[142_33]
6-12	624-633	formation	event[33]	giv[33]	_	_
6-13	634-635	.	_	_	_	_

#Text=However , the therapeutic dose of BMP2 is very expensive , and there are some life-threatening side effects that can occur with larger doses .
7-1	636-643	However	_	_	_	_
7-2	644-645	,	_	_	_	_
7-3	646-649	the	abstract[34]	new[34]	ana	8-3[0_34]
7-4	650-661	therapeutic	abstract[34]	new[34]	_	_
7-5	662-666	dose	abstract[34]	new[34]	_	_
7-6	667-669	of	abstract[34]	new[34]	_	_
7-7	670-674	BMP2	abstract[34]|abstract	new[34]|giv	coref	8-16[44_0]
7-8	675-677	is	_	_	_	_
7-9	678-682	very	_	_	_	_
7-10	683-692	expensive	_	_	_	_
7-11	693-694	,	_	_	_	_
7-12	695-698	and	_	_	_	_
7-13	699-704	there	_	_	_	_
7-14	705-708	are	_	_	_	_
7-15	709-713	some	abstract[38]	new[38]	coref	8-20[46_38]
7-16	714-730	life-threatening	abstract|abstract[38]	new|new[38]	_	_
7-17	731-735	side	abstract|abstract[38]	new|new[38]	coref	25-8
7-18	736-743	effects	abstract[38]	new[38]	_	_
7-19	744-748	that	abstract[38]	new[38]	_	_
7-20	749-752	can	abstract[38]	new[38]	_	_
7-21	753-758	occur	abstract[38]	new[38]	_	_
7-22	759-763	with	abstract[38]	new[38]	_	_
7-23	764-770	larger	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-24	771-776	doses	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-25	777-778	.	_	_	_	_

#Text=Hence , it is necessary to find additional agents or methods for the improvement of BMP2 itself to intensify the osteogenic effects of BMP2 .
8-1	779-784	Hence	_	_	_	_
8-2	785-786	,	_	_	_	_
8-3	787-789	it	abstract	giv	ana	8-17
8-4	790-792	is	_	_	_	_
8-5	793-802	necessary	_	_	_	_
8-6	803-805	to	_	_	_	_
8-7	806-810	find	_	_	_	_
8-8	811-821	additional	person[41]	new[41]	_	_
8-9	822-828	agents	person[41]	new[41]	_	_
8-10	829-831	or	_	_	_	_
8-11	832-839	methods	abstract[42]	new[42]	_	_
8-12	840-843	for	abstract[42]	new[42]	_	_
8-13	844-847	the	abstract[42]|abstract[43]	new[42]|new[43]	_	_
8-14	848-859	improvement	abstract[42]|abstract[43]	new[42]|new[43]	_	_
8-15	860-862	of	abstract[42]|abstract[43]	new[42]|new[43]	_	_
8-16	863-867	BMP2	abstract[42]|abstract[43]|abstract[44]	new[42]|new[43]|giv[44]	coref	8-24[0_44]
8-17	868-874	itself	abstract[42]|abstract[43]|abstract[44]|abstract	new[42]|new[43]|giv[44]|giv	_	_
8-18	875-877	to	_	_	_	_
8-19	878-887	intensify	_	_	_	_
8-20	888-891	the	abstract[46]	giv[46]	coref	9-19[56_46]
8-21	892-902	osteogenic	abstract[46]	giv[46]	_	_
8-22	903-910	effects	abstract[46]	giv[46]	_	_
8-23	911-913	of	abstract[46]	giv[46]	_	_
8-24	914-918	BMP2	abstract[46]|abstract	giv[46]|giv	coref	9-4
8-25	919-920	.	_	_	_	_

#Text=The combination of BMP2 and these small molecules can promote BMP2-mediated osteoblast differentiation and reduces the risk of its side effects in the treatment of bone diseases .
9-1	921-924	The	abstract[48]	new[48]	_	_
9-2	925-936	combination	abstract[48]	new[48]	_	_
9-3	937-939	of	abstract[48]	new[48]	_	_
9-4	940-944	BMP2	abstract[48]|abstract	new[48]|giv	ana	9-19
9-5	945-948	and	abstract[48]	new[48]	_	_
9-6	949-954	these	abstract[48]|substance[50]	new[48]|new[50]	coref	10-6[61_50]
9-7	955-960	small	abstract[48]|substance[50]	new[48]|new[50]	_	_
9-8	961-970	molecules	abstract[48]|substance[50]	new[48]|new[50]	_	_
9-9	971-974	can	_	_	_	_
9-10	975-982	promote	_	_	_	_
9-11	983-996	BMP2-mediated	abstract|event[53]	new|giv[53]	coref|coref	15-14[105_53]|23-7
9-12	997-1007	osteoblast	event|event[53]	giv|giv[53]	coref	22-13
9-13	1008-1023	differentiation	event[53]	giv[53]	_	_
9-14	1024-1027	and	_	_	_	_
9-15	1028-1035	reduces	_	_	_	_
9-16	1036-1039	the	abstract[54]	new[54]	_	_
9-17	1040-1044	risk	abstract[54]	new[54]	_	_
9-18	1045-1047	of	abstract[54]	new[54]	_	_
9-19	1048-1051	its	abstract[54]|abstract|abstract[56]	new[54]|giv|giv[56]	coref|coref	10-11|14-21[92_56]
9-20	1052-1056	side	abstract[54]|abstract[56]	new[54]|giv[56]	_	_
9-21	1057-1064	effects	abstract[54]|abstract[56]	new[54]|giv[56]	_	_
9-22	1065-1067	in	_	_	_	_
9-23	1068-1071	the	event[57]	new[57]	_	_
9-24	1072-1081	treatment	event[57]	new[57]	_	_
9-25	1082-1084	of	event[57]	new[57]	_	_
9-26	1085-1089	bone	event[57]|object|abstract[59]	new[57]|giv|new[59]	coref|coref	13-32|25-16[183_59]
9-27	1090-1098	diseases	event[57]|abstract[59]	new[57]|new[59]	_	_
9-28	1099-1100	.	_	_	_	_

#Text=From a clinical perspective , these small molecules that regulate BMP2 activity provide powerful tools for the treatment of osteoporosis and fracture repair .
10-1	1101-1105	From	_	_	_	_
10-2	1106-1107	a	abstract[60]	new[60]	_	_
10-3	1108-1116	clinical	abstract[60]	new[60]	_	_
10-4	1117-1128	perspective	abstract[60]	new[60]	_	_
10-5	1129-1130	,	_	_	_	_
10-6	1131-1136	these	substance[61]	giv[61]	_	_
10-7	1137-1142	small	substance[61]	giv[61]	_	_
10-8	1143-1152	molecules	substance[61]	giv[61]	_	_
10-9	1153-1157	that	substance[61]	giv[61]	_	_
10-10	1158-1166	regulate	substance[61]	giv[61]	_	_
10-11	1167-1171	BMP2	substance[61]|abstract|abstract[63]	giv[61]|giv|new[63]	coref	20-10
10-12	1172-1180	activity	substance[61]|abstract[63]	giv[61]|new[63]	_	_
10-13	1181-1188	provide	_	_	_	_
10-14	1189-1197	powerful	abstract[64]	new[64]	_	_
10-15	1198-1203	tools	abstract[64]	new[64]	_	_
10-16	1204-1207	for	abstract[64]	new[64]	_	_
10-17	1208-1211	the	abstract[64]|event[65]	new[64]|new[65]	_	_
10-18	1212-1221	treatment	abstract[64]|event[65]	new[64]|new[65]	_	_
10-19	1222-1224	of	abstract[64]|event[65]	new[64]|new[65]	_	_
10-20	1225-1237	osteoporosis	abstract[64]|event[65]|abstract|abstract[67]	new[64]|new[65]|giv|giv[67]	coref	13-35
10-21	1238-1241	and	abstract[64]|event[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-22	1242-1250	fracture	abstract[64]|event[65]|abstract[67]|abstract|abstract[69]	new[64]|new[65]|giv[67]|new|new[69]	coref	14-8[0_69]
10-23	1251-1257	repair	abstract[64]|event[65]|abstract[67]|abstract[69]	new[64]|new[65]|giv[67]|new[69]	_	_
10-24	1258-1259	.	_	_	_	_

#Text=Icariin ( ICA ) ( the chemical structure is shown in
11-1	1260-1267	Icariin	person	new	_	_
11-2	1268-1269	(	_	_	_	_
11-3	1270-1273	ICA	place	new	coref	14-10
11-4	1274-1275	)	_	_	_	_
11-5	1276-1277	(	_	_	_	_
11-6	1278-1281	the	abstract[72]	new[72]	_	_
11-7	1282-1290	chemical	abstract[72]	new[72]	_	_
11-8	1291-1300	structure	abstract[72]	new[72]	_	_
11-9	1301-1303	is	_	_	_	_
11-10	1304-1309	shown	_	_	_	_
11-11	1310-1312	in	_	_	_	_

#Text=Figure 1
12-1	1313-1319	Figure	abstract[73]	new[73]	_	_
12-2	1320-1321	1	abstract[73]	new[73]	_	_

#Text=) is the main active flavonoid glucoside from herbs of the genus Epimedium ; these herbs are used in traditional Chinese medicine and have long been prescribed for the treatment of bone fractures and osteoporosis as a bone-protecting agent .
13-1	1322-1323	)	_	_	_	_
13-2	1324-1326	is	_	_	_	_
13-3	1327-1330	the	substance[75]	new[75]	_	_
13-4	1331-1335	main	substance[75]	new[75]	_	_
13-5	1336-1342	active	substance[75]	new[75]	_	_
13-6	1343-1352	flavonoid	object|substance[75]	new|new[75]	_	_
13-7	1353-1362	glucoside	substance[75]	new[75]	_	_
13-8	1363-1367	from	substance[75]	new[75]	_	_
13-9	1368-1373	herbs	substance[75]|plant[76]	new[75]|new[76]	coref	13-15[79_76]
13-10	1374-1376	of	substance[75]|plant[76]	new[75]|new[76]	_	_
13-11	1377-1380	the	substance[75]|plant[76]|plant[77]|place[78]	new[75]|new[76]|new[77]|new[78]	_	_
13-12	1381-1386	genus	substance[75]|plant[76]|plant[77]|place[78]	new[75]|new[76]|new[77]|new[78]	_	_
13-13	1387-1396	Epimedium	substance[75]|plant[76]|place[78]	new[75]|new[76]|new[78]	_	_
13-14	1397-1398	;	_	_	_	_
13-15	1399-1404	these	plant[79]	giv[79]	_	_
13-16	1405-1410	herbs	plant[79]	giv[79]	_	_
13-17	1411-1414	are	_	_	_	_
13-18	1415-1419	used	_	_	_	_
13-19	1420-1422	in	_	_	_	_
13-20	1423-1434	traditional	abstract[80]	new[80]	_	_
13-21	1435-1442	Chinese	abstract[80]	new[80]	_	_
13-22	1443-1451	medicine	abstract[80]	new[80]	_	_
13-23	1452-1455	and	_	_	_	_
13-24	1456-1460	have	_	_	_	_
13-25	1461-1465	long	_	_	_	_
13-26	1466-1470	been	_	_	_	_
13-27	1471-1481	prescribed	_	_	_	_
13-28	1482-1485	for	_	_	_	_
13-29	1486-1489	the	event[81]	new[81]	coref	15-9[103_81]
13-30	1490-1499	treatment	event[81]	new[81]	_	_
13-31	1500-1502	of	event[81]	new[81]	_	_
13-32	1503-1507	bone	event[81]|object|event[83]|event[84]	new[81]|giv|giv[83]|giv[84]	coref|coref	13-32[84_83]|14-5
13-33	1508-1517	fractures	event[81]|event[83]|event[84]	new[81]|giv[83]|giv[84]	_	_
13-34	1518-1521	and	event[81]|event[84]	new[81]|giv[84]	_	_
13-35	1522-1534	osteoporosis	event[81]|event[84]|abstract	new[81]|giv[84]|giv	coref	25-20
13-36	1535-1537	as	_	_	_	_
13-37	1538-1539	a	substance[86]	new[86]	_	_
13-38	1540-1555	bone-protecting	substance[86]	new[86]	_	_
13-39	1556-1561	agent	substance[86]	new[86]	_	_
13-40	1562-1563	.	_	_	_	_

#Text=In addition to promoting bone regeneration and repair , ICA also has many beneficial pharmacological and biological activities , including neuroprotective effects ; protective effects against atherosclerosis ; antitumor effects ; anti-inflammatory and antioxidant effects ; and improved sexual function effects .
14-1	1564-1566	In	_	_	_	_
14-2	1567-1575	addition	_	_	_	_
14-3	1576-1578	to	_	_	_	_
14-4	1579-1588	promoting	_	_	_	_
14-5	1589-1593	bone	object|event[88]	giv|new[88]	coref	15-18
14-6	1594-1606	regeneration	event[88]	new[88]	_	_
14-7	1607-1610	and	_	_	_	_
14-8	1611-1617	repair	abstract	giv	_	_
14-9	1618-1619	,	_	_	_	_
14-10	1620-1623	ICA	place	giv	coref	15-11
14-11	1624-1628	also	_	_	_	_
14-12	1629-1632	has	_	_	_	_
14-13	1633-1637	many	abstract[91]	new[91]	_	_
14-14	1638-1648	beneficial	abstract[91]	new[91]	_	_
14-15	1649-1664	pharmacological	abstract[91]	new[91]	_	_
14-16	1665-1668	and	abstract[91]	new[91]	_	_
14-17	1669-1679	biological	abstract[91]	new[91]	_	_
14-18	1680-1690	activities	abstract[91]	new[91]	_	_
14-19	1691-1692	,	abstract[91]	new[91]	_	_
14-20	1693-1702	including	abstract[91]	new[91]	_	_
14-21	1703-1718	neuroprotective	abstract[91]|abstract[92]|abstract[93]	new[91]|giv[92]|giv[93]	coref|coref	14-21[93_92]|14-24[94_93]
14-22	1719-1726	effects	abstract[91]|abstract[92]|abstract[93]	new[91]|giv[92]|giv[93]	_	_
14-23	1727-1728	;	abstract[91]|abstract[93]	new[91]|giv[93]	_	_
14-24	1729-1739	protective	abstract[91]|abstract[93]|abstract[94]	new[91]|giv[93]|giv[94]	coref	14-29[97_94]
14-25	1740-1747	effects	abstract[91]|abstract[93]|abstract[94]	new[91]|giv[93]|giv[94]	_	_
14-26	1748-1755	against	abstract[91]|abstract[93]|abstract[94]	new[91]|giv[93]|giv[94]	_	_
14-27	1756-1771	atherosclerosis	abstract[91]|abstract[93]|abstract[94]|abstract	new[91]|giv[93]|giv[94]|new	_	_
14-28	1772-1773	;	abstract[91]|abstract[93]	new[91]|giv[93]	_	_
14-29	1774-1783	antitumor	abstract[91]|abstract[93]|abstract|abstract[97]	new[91]|giv[93]|new|giv[97]	coref	14-32[98_97]
14-30	1784-1791	effects	abstract[91]|abstract[93]|abstract[97]	new[91]|giv[93]|giv[97]	_	_
14-31	1792-1793	;	abstract[91]|abstract[93]	new[91]|giv[93]	_	_
14-32	1794-1811	anti-inflammatory	abstract[91]|abstract[93]|abstract[98]	new[91]|giv[93]|giv[98]	coref	14-38[100_98]
14-33	1812-1815	and	abstract[91]|abstract[93]|abstract[98]	new[91]|giv[93]|giv[98]	_	_
14-34	1816-1827	antioxidant	abstract[91]|abstract[93]|abstract[98]	new[91]|giv[93]|giv[98]	_	_
14-35	1828-1835	effects	abstract[91]|abstract[93]|abstract[98]	new[91]|giv[93]|giv[98]	_	_
14-36	1836-1837	;	abstract[91]|abstract[93]	new[91]|giv[93]	_	_
14-37	1838-1841	and	abstract[91]|abstract[93]	new[91]|giv[93]	_	_
14-38	1842-1850	improved	abstract[91]|abstract[93]|abstract[100]	new[91]|giv[93]|giv[100]	coref	16-8[114_100]
14-39	1851-1857	sexual	abstract[91]|abstract[93]|abstract[99]|abstract[100]	new[91]|giv[93]|new[99]|giv[100]	_	_
14-40	1858-1866	function	abstract[91]|abstract[93]|abstract[99]|abstract[100]	new[91]|giv[93]|new[99]|giv[100]	_	_
14-41	1867-1874	effects	abstract[91]|abstract[93]|abstract[100]	new[91]|giv[93]|giv[100]	_	_
14-42	1875-1876	.	_	_	_	_

#Text=Several animal and cell studies have shown that treatment with ICA can increase osteogenic differentiation and reduce bone loss in vivo and in vitro .
15-1	1877-1884	Several	abstract[102]	new[102]	coref	18-1[123_102]
15-2	1885-1891	animal	animal|abstract[102]	new|new[102]	_	_
15-3	1892-1895	and	abstract[102]	new[102]	_	_
15-4	1896-1900	cell	abstract[102]	new[102]	_	_
15-5	1901-1908	studies	abstract[102]	new[102]	_	_
15-6	1909-1913	have	_	_	_	_
15-7	1914-1919	shown	_	_	_	_
15-8	1920-1924	that	_	_	_	_
15-9	1925-1934	treatment	event[103]	giv[103]	_	_
15-10	1935-1939	with	event[103]	giv[103]	_	_
15-11	1940-1943	ICA	event[103]|place	giv[103]|giv	coref	16-6
15-12	1944-1947	can	_	_	_	_
15-13	1948-1956	increase	_	_	_	_
15-14	1957-1967	osteogenic	event[105]	giv[105]	coref	17-10[121_105]
15-15	1968-1983	differentiation	event[105]	giv[105]	_	_
15-16	1984-1987	and	_	_	_	_
15-17	1988-1994	reduce	_	_	_	_
15-18	1995-1999	bone	object|event[107]	giv|new[107]	coref	16-10
15-19	2000-2004	loss	event[107]	new[107]	_	_
15-20	2005-2007	in	_	_	_	_
15-21	2008-2012	vivo	place	new	_	_
15-22	2013-2016	and	_	_	_	_
15-23	2017-2019	in	_	_	_	_
15-24	2020-2025	vitro	organization	new	_	_
15-25	2026-2027	.	_	_	_	_

#Text=The extremely low cost of ICA and its strong bone regenerative effects indicate its potential in clinical applications .
16-1	2028-2031	The	abstract[110]	new[110]	_	_
16-2	2032-2041	extremely	abstract[110]	new[110]	_	_
16-3	2042-2045	low	abstract[110]	new[110]	_	_
16-4	2046-2050	cost	abstract[110]	new[110]	_	_
16-5	2051-2053	of	abstract[110]	new[110]	_	_
16-6	2054-2057	ICA	abstract[110]|place	new[110]|giv	ana	16-8
16-7	2058-2061	and	_	_	_	_
16-8	2062-2065	its	place|abstract[114]	giv|giv[114]	ana	16-14
16-9	2066-2072	strong	abstract[114]	giv[114]	_	_
16-10	2073-2077	bone	object|abstract[114]	giv|giv[114]	coref	19-27
16-11	2078-2090	regenerative	abstract[114]	giv[114]	_	_
16-12	2091-2098	effects	abstract[114]	giv[114]	_	_
16-13	2099-2107	indicate	_	_	_	_
16-14	2108-2111	its	place|abstract[116]	giv|new[116]	coref	20-8
16-15	2112-2121	potential	abstract[116]	new[116]	_	_
16-16	2122-2124	in	abstract[116]	new[116]	_	_
16-17	2125-2133	clinical	abstract[116]|abstract[117]	new[116]|new[117]	_	_
16-18	2134-2146	applications	abstract[116]|abstract[117]	new[116]|new[117]	_	_
16-19	2147-2148	.	_	_	_	_

#Text=The cAMP/PKA/CREB axis is a vital pathway that regulates osteogenic differentiation and mineralization .
17-1	2149-2152	The	abstract[119]	new[119]	coref	17-5[120_119]
17-2	2153-2166	cAMP/PKA/CREB	substance|abstract[119]	new|new[119]	coref	18-14
17-3	2167-2171	axis	abstract[119]	new[119]	_	_
17-4	2172-2174	is	_	_	_	_
17-5	2175-2176	a	abstract[120]	giv[120]	coref	18-13[127_120]
17-6	2177-2182	vital	abstract[120]	giv[120]	_	_
17-7	2183-2190	pathway	abstract[120]	giv[120]	_	_
17-8	2191-2195	that	abstract[120]	giv[120]	_	_
17-9	2196-2205	regulates	abstract[120]	giv[120]	_	_
17-10	2206-2216	osteogenic	abstract[120]|event[121]	giv[120]|giv[121]	coref	22-12[160_121]
17-11	2217-2232	differentiation	abstract[120]|event[121]	giv[120]|giv[121]	_	_
17-12	2233-2236	and	abstract[120]	giv[120]	_	_
17-13	2237-2251	mineralization	abstract[120]|substance	giv[120]|new	_	_
17-14	2252-2253	.	_	_	_	_

#Text=Several previous studies have reported that PTH affects osteoblastic cells by activating the cAMP/PKA/CREB axis .
18-1	2254-2261	Several	abstract[123]	giv[123]	coref	19-1[128_123]
18-2	2262-2270	previous	abstract[123]	giv[123]	_	_
18-3	2271-2278	studies	abstract[123]	giv[123]	_	_
18-4	2279-2283	have	_	_	_	_
18-5	2284-2292	reported	_	_	_	_
18-6	2293-2297	that	_	_	_	_
18-7	2298-2301	PTH	abstract	new	_	_
18-8	2302-2309	affects	_	_	_	_
18-9	2310-2322	osteoblastic	animal[125]	new[125]	coref	19-8[132_125]
18-10	2323-2328	cells	animal[125]	new[125]	_	_
18-11	2329-2331	by	_	_	_	_
18-12	2332-2342	activating	_	_	_	_
18-13	2343-2346	the	abstract[127]	giv[127]	coref	23-11[168_127]
18-14	2347-2360	cAMP/PKA/CREB	substance|abstract[127]	giv|giv[127]	coref	23-12
18-15	2361-2365	axis	abstract[127]	giv[127]	_	_
18-16	2366-2367	.	_	_	_	_

#Text=Several studies have reported that pretreatment of human mesenchymal stem cells ( MSCs ) with cAMP analogs , adenylate cyclase activators or phosphodiesterase inhibitors can enhance bone formation .
19-1	2368-2375	Several	abstract[128]	giv[128]	_	_
19-2	2376-2383	studies	abstract[128]	giv[128]	_	_
19-3	2384-2388	have	_	_	_	_
19-4	2389-2397	reported	_	_	_	_
19-5	2398-2402	that	_	_	_	_
19-6	2403-2415	pretreatment	event[129]	new[129]	_	_
19-7	2416-2418	of	event[129]	new[129]	_	_
19-8	2419-2424	human	event[129]|animal[132]	new[129]|giv[132]	coref	21-15[154_132]
19-9	2425-2436	mesenchymal	event[129]|person|animal[132]	new[129]|new|giv[132]	_	_
19-10	2437-2441	stem	event[129]|plant|animal[132]	new[129]|new|giv[132]	_	_
19-11	2442-2447	cells	event[129]|animal[132]	new[129]|giv[132]	_	_
19-12	2448-2449	(	event[129]	new[129]	_	_
19-13	2450-2454	MSCs	event[129]|abstract	new[129]|new	_	_
19-14	2455-2456	)	event[129]	new[129]	_	_
19-15	2457-2461	with	event[129]	new[129]	_	_
19-16	2462-2466	cAMP	event[129]|substance|object[135]	new[129]|new|new[135]	_	_
19-17	2467-2474	analogs	event[129]|object[135]	new[129]|new[135]	_	_
19-18	2475-2476	,	event[129]	new[129]	_	_
19-19	2477-2486	adenylate	event[129]|substance|abstract[138]	new[129]|new|new[138]	_	_
19-20	2487-2494	cyclase	event[129]|abstract|abstract[138]	new[129]|new|new[138]	_	_
19-21	2495-2505	activators	event[129]|abstract[138]	new[129]|new[138]	_	_
19-22	2506-2508	or	event[129]	new[129]	_	_
19-23	2509-2526	phosphodiesterase	event[129]|abstract|abstract[140]	new[129]|new|new[140]	_	_
19-24	2527-2537	inhibitors	event[129]|abstract[140]	new[129]|new[140]	_	_
19-25	2538-2541	can	_	_	_	_
19-26	2542-2549	enhance	_	_	_	_
19-27	2550-2554	bone	object|event[142]	giv|giv[142]	coref	25-16
19-28	2555-2564	formation	event[142]	giv[142]	_	_
19-29	2565-2566	.	_	_	_	_

#Text=In the present study , we combined ICA and BMP2 to promote osteogenesis for the first time .
20-1	2567-2569	In	_	_	_	_
20-2	2570-2573	the	abstract[143]	new[143]	_	_
20-3	2574-2581	present	abstract[143]	new[143]	_	_
20-4	2582-2587	study	abstract[143]	new[143]	_	_
20-5	2588-2589	,	_	_	_	_
20-6	2590-2592	we	person	acc	ana	21-1
20-7	2593-2601	combined	abstract	new	coref|none	22-4[156_0]|20-7[0_176]
20-8	2602-2605	ICA	place	giv	coref	21-6
20-9	2606-2609	and	_	_	_	_
20-10	2610-2614	BMP2	abstract	giv	coref	21-13
20-11	2615-2617	to	_	_	_	_
20-12	2618-2625	promote	_	_	_	_
20-13	2626-2638	osteogenesis	abstract	new	coref	23-7[165_0]
20-14	2639-2642	for	_	_	_	_
20-15	2643-2646	the	time[148]	new[148]	_	_
20-16	2647-2652	first	time[148]	new[148]	_	_
20-17	2653-2657	time	time[148]	new[148]	_	_
20-18	2658-2659	.	_	_	_	_

#Text=We aimed to determine whether ICA could enhance the osteogenic induction of BMP2 in C2C12 cells .
21-1	2660-2662	We	person	giv	ana	22-1
21-2	2663-2668	aimed	_	_	_	_
21-3	2669-2671	to	_	_	_	_
21-4	2672-2681	determine	_	_	_	_
21-5	2682-2689	whether	_	_	_	_
21-6	2690-2693	ICA	place	giv	coref	22-7
21-7	2694-2699	could	_	_	_	_
21-8	2700-2707	enhance	_	_	_	_
21-9	2708-2711	the	event[151]	new[151]	_	_
21-10	2712-2722	osteogenic	event[151]	new[151]	_	_
21-11	2723-2732	induction	event[151]	new[151]	_	_
21-12	2733-2735	of	event[151]	new[151]	_	_
21-13	2736-2740	BMP2	event[151]|abstract	new[151]|giv	coref	22-9
21-14	2741-2743	in	_	_	_	_
21-15	2744-2749	C2C12	substance|animal[154]	new|giv[154]	_	_
21-16	2750-2755	cells	animal[154]	giv[154]	_	_
21-17	2756-2757	.	_	_	_	_

#Text=We concluded that the combination of ICA and BMP2 could promote BMP2-mediated osteoblast differentiation in a dose-dependent manner .
22-1	2758-2760	We	person	giv	ana	23-1
22-2	2761-2770	concluded	_	_	_	_
22-3	2771-2775	that	_	_	_	_
22-4	2776-2779	the	abstract[156]	new[156]	coref	25-1[176_156]
22-5	2780-2791	combination	abstract[156]	new[156]	_	_
22-6	2792-2794	of	abstract[156]	new[156]	_	_
22-7	2795-2798	ICA	abstract[156]|place	new[156]|giv	coref	23-5
22-8	2799-2802	and	abstract[156]	new[156]	_	_
22-9	2803-2807	BMP2	abstract[156]|abstract	new[156]|giv	coref	24-12
22-10	2808-2813	could	_	_	_	_
22-11	2814-2821	promote	_	_	_	_
22-12	2822-2835	BMP2-mediated	event[160]	giv[160]	_	_
22-13	2836-2846	osteoblast	event|event[160]	giv|giv[160]	_	_
22-14	2847-2862	differentiation	event[160]	giv[160]	_	_
22-15	2863-2865	in	_	_	_	_
22-16	2866-2867	a	abstract[161]	new[161]	_	_
22-17	2868-2882	dose-dependent	abstract[161]	new[161]	_	_
22-18	2883-2889	manner	abstract[161]	new[161]	_	_
22-19	2890-2891	.	_	_	_	_

#Text=We also found that ICA stimulates BMP2-mediated osteogenesis by activating the cAMP/PKA/CREB signaling pathway .
23-1	2892-2894	We	person	giv	_	_
23-2	2895-2899	also	_	_	_	_
23-3	2900-2905	found	_	_	_	_
23-4	2906-2910	that	_	_	_	_
23-5	2911-2914	ICA	place	giv	coref	24-3
23-6	2915-2925	stimulates	_	_	_	_
23-7	2926-2939	BMP2-mediated	abstract|abstract[165]	giv|giv[165]	_	_
23-8	2940-2952	osteogenesis	abstract[165]	giv[165]	_	_
23-9	2953-2955	by	_	_	_	_
23-10	2956-2966	activating	_	_	_	_
23-11	2967-2970	the	abstract[168]	giv[168]	_	_
23-12	2971-2984	cAMP/PKA/CREB	substance|abstract[168]	giv|giv[168]	_	_
23-13	2985-2994	signaling	abstract|abstract[168]	new|giv[168]	_	_
23-14	2995-3002	pathway	abstract[168]	giv[168]	_	_
23-15	3003-3004	.	_	_	_	_

#Text=Therefore , ICA is a promising candidate as an alternative for BMP2 or as a promoter for enhancing the therapeutic effects of BMP2 .
24-1	3005-3014	Therefore	_	_	_	_
24-2	3015-3016	,	_	_	_	_
24-3	3017-3020	ICA	place	giv	_	_
24-4	3021-3023	is	_	_	_	_
24-5	3024-3025	a	person[170]	new[170]	_	_
24-6	3026-3035	promising	person[170]	new[170]	_	_
24-7	3036-3045	candidate	person[170]	new[170]	_	_
24-8	3046-3048	as	person[170]	new[170]	_	_
24-9	3049-3051	an	person[170]|abstract[171]	new[170]|new[171]	_	_
24-10	3052-3063	alternative	person[170]|abstract[171]	new[170]|new[171]	_	_
24-11	3064-3067	for	person[170]|abstract[171]	new[170]|new[171]	_	_
24-12	3068-3072	BMP2	person[170]|abstract[171]|abstract	new[170]|new[171]|giv	coref	24-23
24-13	3073-3075	or	_	_	_	_
24-14	3076-3078	as	_	_	_	_
24-15	3079-3080	a	person[173]	new[173]	_	_
24-16	3081-3089	promoter	person[173]	new[173]	_	_
24-17	3090-3093	for	person[173]	new[173]	_	_
24-18	3094-3103	enhancing	person[173]	new[173]	_	_
24-19	3104-3107	the	person[173]|abstract[174]	new[173]|new[174]	coref	25-8[179_174]
24-20	3108-3119	therapeutic	person[173]|abstract[174]	new[173]|new[174]	_	_
24-21	3120-3127	effects	person[173]|abstract[174]	new[173]|new[174]	_	_
24-22	3128-3130	of	person[173]|abstract[174]	new[173]|new[174]	_	_
24-23	3131-3135	BMP2	person[173]|abstract[174]|abstract	new[173]|new[174]|giv	coref	25-11
24-24	3136-3137	.	_	_	_	_

#Text=This combination will reduce the risk of side effects from BMP2 in the treatment of bone diseases such as osteoporosis .
25-1	3138-3142	This	abstract[176]	giv[176]	_	_
25-2	3143-3154	combination	abstract[176]	giv[176]	_	_
25-3	3155-3159	will	_	_	_	_
25-4	3160-3166	reduce	_	_	_	_
25-5	3167-3170	the	abstract[177]	new[177]	_	_
25-6	3171-3175	risk	abstract[177]	new[177]	_	_
25-7	3176-3178	of	abstract[177]	new[177]	_	_
25-8	3179-3183	side	abstract[177]|abstract|abstract[179]	new[177]|giv|giv[179]	_	_
25-9	3184-3191	effects	abstract[177]|abstract[179]	new[177]|giv[179]	_	_
25-10	3192-3196	from	abstract[177]|abstract[179]	new[177]|giv[179]	_	_
25-11	3197-3201	BMP2	abstract[177]|abstract[179]|abstract	new[177]|giv[179]|giv	_	_
25-12	3202-3204	in	_	_	_	_
25-13	3205-3208	the	abstract[181]	new[181]	_	_
25-14	3209-3218	treatment	abstract[181]	new[181]	_	_
25-15	3219-3221	of	abstract[181]	new[181]	_	_
25-16	3222-3226	bone	abstract[181]|object|abstract[183]	new[181]|giv|giv[183]	_	_
25-17	3227-3235	diseases	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
25-18	3236-3240	such	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
25-19	3241-3243	as	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
25-20	3244-3256	osteoporosis	abstract[181]|abstract[183]|abstract	new[181]|giv[183]|giv	_	_
25-21	3257-3258	.	_	_	_	_
